Edgewise Therapeutics (EWTX) shares went up 29% in Thursday's premarket activity after announcing that EDG-7500, an investigational treatment for cardiomyopathy, was found to be well-tolerated in two early trials.
Results showed that EDG-7500 was well-tolerated in both a phase 1 study on healthy subjects and a phase 2 study on patients with obstructive hypertrophic cardiomyopathy, with no significant side effects such as changes in the heart's pumping of blood, Edgewise said.
Edgewise said it began dosing patients for a 28-day part of the obstructive ECM trial and initial results are expected in Q1 next year.
Price: 24.60, Change: +5.53, Percent Change: +28.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.